Know Cancer

forgot password

Vitamin D/Calcium Polyp Prevention Study

Phase 2/Phase 3
45 Years
75 Years
Open (Enrolling)
Colorectal Cancer, Polyps, Adenomas

Thank you

Trial Information

Vitamin D/Calcium Polyp Prevention Study

This study is a double-blind, placebo-controlled trial of vitamin D and/or calcium
supplementation for the prevention of large bowel adenomas. Subjects will be recruited from
10 Study Centers in North America. Eligible subjects will have had at least one large bowel
adenoma removed in the 4 months prior to study entry and no remaining polyps in the bowel
after complete colonoscopic examination. Participants will be randomized in a modified 2 x
2 factorial design to vitamin D (1000 IU/day), calcium carbonate (1200 mg elemental
calcium/day), both agents, or placebo only. Women who decline to forego calcium
supplementation will be randomized only to calcium alone or to calcium plus vitamin D.
Randomization will be stratified by gender, study center of recruitment, and anticipated
follow-up interval (see below), and will be conducted separately for female subjects
randomized only to vitamin D. We anticipate enrolling about 2500 participants to reach a
total of approximately 2000 randomized subjects. As safety measures, blood levels of
calcium, creatinine, and 25-(OH)-vitamin D will be obtained at baseline and 1 year after
randomization, as well as 3 years after randomization for subjects with a 5-year
surveillance cycle. Every six months after randomization subjects will complete a
questionnaire regarding compliance with study agents, use of medications and vitamin/mineral
supplements, illnesses, hospitalizations, and dietary intake of calcium and vitamin D. The
endpoint of the study will be new adenomas detected on follow-up colonoscopy. These
examinations are scheduled to occur either 3 years or 5 years after the qualifying
examination, depending on the follow-up interval recommended by each patient's endoscopist.
Some patients may, for medical reasons, have a colonoscopy at a time other than 3 or 5 years
after the qualifying examination. Information from these exams will be included in analyses
where appropriate. In the primary analyses, the occurrence of new neoplastic polyps in the
interval between randomization and the follow-up exam will be compared between subjects
randomized to vitamin D (with or without calcium) versus those randomized to placebo (with
or without calcium), between subjects randomized to calcium (with or without vitamin D)
versus those randomized to placebo (with or without vitamin D, excluding women electing to
receive calcium and therefore cannot participate in the calcium component of the study), and
between those randomized to calcium plus vitamin D versus those randomized to calcium alone.
In secondary analyses, we will examine the effect of calcium plus vitamin D versus vitamin
D alone, and the impact of baseline vitamin D levels and vitamin D receptor (VDR)
polymorphisms on the vitamin D effects. Effects on advanced adenomas will also be assessed.

Inclusion Criteria:

- One or more histologically verified neoplastic polyp (adenoma) that is at least 2 mm
in size removed from the large bowel with the entire large bowel examined by
colonoscopy and documented to be free of further polyps or areas suspicious for
neoplasia within 120 days of study entry

- Anticipated colonoscopic follow-up three years or five years after the qualifying

- Age between 45 and 75 years at enrollment

- (Women)Agreement to avoid pregnancy (i.e., use of standard contraception)

- Willingness to forego calcium supplementation (including multivitamins containing
calcium) or, for women only, option of taking calcium supplementation of 1200
mg/daily (contained in the study pills)

- Willingness to forego vitamin D supplementation (including multivitamins containing
vitamin D)

- Agreement to daily dietary intake of the equivalent of not more than 1200 mg calcium

- Agreement to daily dietary intake of the equivalent of not more than 400 IU vitamin D

- Blood calcium level within normal range

- Blood creatinine level not to exceed 20% above upper limit of normal

- Serum 25-(OH)-vitamin D within lower limit of normal to 70 ng/ml

- Ability and willingness to follow the study protocol, as indicated by provision of
informed consent to participate

- Good general health, with no severely debilitating diseases or active malignancy that
might compromise the patient's ability to complete the study

Exclusion Criteria:

General exclusionary criteria:

- Participation in another colorectal (bowel) study (intervention study) in the past 5

- Current participation in any other clinical trial (intervention study)

- Pregnancy or lactation

- A diagnosis of narcotic or alcohol dependence in the past 5 years

- A diagnosis of dementia (e.g. Alzheimer's) in the past 5 years

- A diagnosis of a significant psychiatric disability (e.g. Schizophrenia, refractory
bipolar disorder, current severe depression) in the past 5 years

Exclusions due to derangement of calcium metabolism or indications /contraindications to
study agents:

- Any diagnosis of kidney stones

- A diagnosis of granulomatous diseases, e.g. sarcoidosis, active chronic fungal or
mycobacterial infections (tuberculosis, histoplasmosis, coccidioidomycosis,
blastomycosis), berylliosis, Wegener's granulomatosis in the past 5 years

- A diagnosis of hyperparathyroidism or other serious disturbance of calcium metabolism
in the past 5 years

- A diagnosis of severe kidney disease, e.g. chronic renal failure in the past 5 years

- A diagnosis of unexplained hypercalcemia in the past 5 years

- Any Diagnosis of osteoporosis with physician recommendation for treatment of low bone

- A diagnosis of two or more low trauma fractures in the past 5 years

- A diagnosis of a medical condition requiring treatment with vitamin D (e.g.
osteomalacia) in the past 5 years

Exclusions due to intestinal or bowel problems:

- Any diagnosis of invasive carcinoma of the large bowel (even if confined to a polyp)

- Any diagnosis of familial colorectal cancer syndromes, e.g. Familial Adenomatous
Polyposis (FAP) (including Gardner syndrome, Turcot's syndrome), Hereditary
Nonpolyposis Colorectal Cancer (HNPCC), Hamartomatous Polyposis syndromes (including
Peutz-Jeghers or Familial Juvenile Polyposis)

- Any diagnosis of inflammatory bowel disease, e.g. Crohn's Disease, Ulcerative Colitis

- A diagnosis of chronic intestinal malabsorption syndromes, e.g. celiac sprue,
bacterial overgrowth, chronic pancreatitis, pancreatic insufficiency in the past 5

- Any large bowel resection

Exclusions due to poor health:

- A diagnosis of malignancy, other than non-melanoma skin cancer in the past 5 years

- A diagnosis of severe lung disease - class 3 or 4 (e.g. chronic obstructive pulmonary
disease or emphysema requiring oxygen) in the past 5 years

- A diagnosis of severe heart disease: cardiovascular disease functional class 3 or 4
in the past 5 years

- Any diagnosis of severe liver disease, e.g. cirrhosis

Exclusions due to shipping regulations:

- Any current/past HIV positive diagnosis

- Active hepatitis B, defined as : Hep B surface antigen positive

- Active hepatitis C, defined as : measurable hepatitis C RNA

Drug exclusions:

- Use of chronic oral corticosteroid therapy in the past 5 years

- Use of lithium in the past 5 years

- Use of phenytoin's in the past 5 years

- Use of quinidine in the past 5 years

- Use of therapeutic vitamin D in the past 5 years

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Outcome Measure:

Colorectal adenomas

Outcome Time Frame:

1 to 5 years

Safety Issue:


Principal Investigator

John A. Baron, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dartmouth-Hitchcock Medical Center


United States: Food and Drug Administration

Study ID:

5 R01 CA098286-03



Start Date:

July 2004

Completion Date:

December 2017

Related Keywords:

  • Colorectal Cancer
  • Polyps
  • Adenomas
  • Colorectal neoplasms
  • Adenomatous polyps
  • Adenoma
  • Colorectal Neoplasms
  • Polyps



University of Iowa Iowa City, Iowa  52242
Cleveland Clinic Foundation Cleveland, Ohio  44195
University of Colorado Denver, Colorado  80217
University of Minnesota Minneapolis, Minnesota  55455
University of North Carolina Chapel Hill, North Carolina  27599
Emory University Atlanta, Georgia  30322
Dartmouth Hitchcock Medical Center Lebanon, New Hampshire  03756
University of Southern California Los Angeles, California  90033
University of Texas Houston, Texas  77225
University of South Carolina Columbia, South Carolina  29203